Halabi S, Dutta S, Tangen CM, et al. Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel. J Clin Oncol 2019;37:403–410.
Sartor O, Armstrong AJ, Ahaghotu C, et al. Survival of African- American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis 2020;23:517–526.
Poulson MR, Helrich SA, Kenzik KM, et al. The impact of racial residential segregation on prostate cancer diagnosis and treatment. BJU Int 2021;127:636–644.
Riaz IB, Islam M, Ikram W, et al. Disparities in the inclusion of racial and ethnic minority groups and older adults in prostate cancer clinical trials: a meta-analysis. JAMA Oncol 2023;9:180–187.
Deville C Jr, Borno HT. Declining representation and reporting of racial and ethnic minority patients in prostate cancer clinical trials despite persistent health disparities-where progress confronts limitations. JAMA Oncol 2023;9:175–177.
Dess RT, Hartman HE, Mahal BA, et al. Association of Black race with prostate cancer-specific and other-cause mortality. JAMA Oncol 2019;5:975–983.
Bernstein AN, Talwar R, Handorf E, et al. Assessment of prostate cancer treatment among Black and White patients during the COVID-19 pandemic. JAMA Oncol 2021;7:1467–1473.
Loeb S, Borno HT, Gomez S, et al. Representation in online prostate cancer content lacks racial and ethnic diversity: implications for Black and Latinx men. J Urol 2022;207:559–564.
Halabi S, Dutta S, Tangen CM, et al. Comparative survival of Asian and white metastatic castration-resistant prostate cancer men treated with docetaxel. JNCI Cancer Spectr 2020;4:pkaa003.
Würnschimmel C, Wenzel M, Collà Ruvolo C, et al. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. World J Urol 2021;39:3781–3787.
Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352–360.
Surveillance, Epidemiology, and End Results Program. SEER incidence data, 1975–2020. Accessed December 20, 2022. Available at: https://seer.cancer.gov/data/
American College of Surgeons. Cancer programs: National Cancer >Database. Accessed December 20, 2022. Available at: https://www.facs.org/quality-programs/cancer-programs/national-cancer-database/
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399–424.
Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515–526.
Siegel DA, O’Neil ME, Richards TB, et al. Prostate cancer incidence and survival, by stage and race/ethnicity – United States, 2001-2017. MMWR Morb Mortal Wkly Rep 2020;69:1473–1480.
Zhang C, Zhang C, Wang Q, et al. Differences in stage of cancer at diagnosis, treatment, and survival by race and ethnicity among leading cancer types. JAMA Netw Open 2020;3:e202950.
Guinney J, Wang T, Laajala TD, et al. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol 2017;18:132–142.
- Search Google Scholar
- Export Citation
, Guinney J , Wang T , Laajala TD Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol 2017; 18: 132– 142. 27864015
Roy S, Sun Y, Wallis CJD, et al. Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer. Prostate Cancer Prostatic Dis 2023;26:119–125.
Modonutti D, Majdalany SE, Corsi N, et al. A novel prognostic model predicting overall survival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: a multi-trial cohort analysis. Prostate 2022;82:1293–1303.
- Search Google Scholar
- Export Citation
, Modonutti D , Majdalany SE , Corsi N A novel prognostic model predicting overall survival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: a multi-trial cohort analysis. Prostate 2022; 82: 1293– 1303. 35790016
George DJ, Ramaswamy K, Huang A, et al. Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2022;25:524–530.
Zhao H, Howard LE, De Hoedt A, et al. Racial discrepancies in overall survival among men treated with 223radium. J Urol 2020;203:331–337.
George DJ, Halabi S, Heath EI, et al. A prospective trial of abiraterone acetate plus prednisone in Black and white men with metastatic castrate-resistant prostate cancer. Cancer 2021;127:2954–2965.
Marar M, Long Q, Mamtani R, et al. Outcomes among African American and Non-Hispanic white men with metastatic castration-resistant prostate cancer with first-line abiraterone. JAMA Netw Open 2022;5:e2142093.
Agarwal N, Alex AB, Farnham JM, et al. Inherited variants in SULT1E1 and response to abiraterone acetate by men with metastatic castration refractory prostate cancer. J Urol 2016;196:1112–1116.
Liu Y, Zhou JW, Liu CD, et al. Comprehensive signature analysis of drug metabolism differences in the White, Black and Asian prostate cancer patients. Aging (Albany NY) 2021;13:16316–16340.
Prizment AE, McSweeney S, Pankratz N, et al. Prostate cancer mortality associated with aggregate polymorphisms in androgen-regulating genes: the Atherosclerosis Risk in the Communities (ARIC) study. Cancers (Basel) 2021;13:1958.
Sweeney C, Bracarda S, Sternberg CN, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet 2021;398:131–142.
Jamaspishvili T, Berman DM, Ross AE, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol 2018;15:222–234.
Barwick BG, Abramovitz M, Kodani M, et al. Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts. Br J Cancer 2010;102:570–576.
Teng M, Zhou S, Cai C, et al. Pioneer of prostate cancer: past, present and the future of FOXA1. Protein Cell 2021;12:29–38.
Kwan EM, Fettke H, Docanto MM, et al. Prognostic utility of a whole-blood androgen receptor-based gene signature in metastatic castration-resistant prostate cancer. Eur Urol Focus 2021;7:63–70.